{4-[[(R)-2-(N',N''-Dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionyl]-(3-oxo-propyl)-amino]-benzyl}-carbamic acid tert-butyl ester | 195718-04-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: {4-[[(R)-2-(N',N''-Dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionyl]-(3-oxo-propyl)-amino]-benzyl}-carbamic acid tert-butyl ester
• CAS: 195718-04-8
• 化学式: C₄₁H₅₅N₅O₄
• 分子量: 681.919
• InChiKey: XQLVUYYPLDXJEF-DIPNUNPCSA-N

反应信息

• 作为反应物：
  描述：

  {4-[[(R)-2-(N',N''-Dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionyl]-(3-oxo-propyl)-amino]-benzyl}-carbamic acid tert-butyl ester 在 sodium chlorite 、 氨基磺酸 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 3-{[4-(tert-Butoxycarbonylamino-methyl)-phenyl]-[(R)-2-(N',N''-dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionyl]-amino}-propionic acid
  参考文献：
  名称：

  Nonpeptide bradykinin antagonist analogs based on a model of a Sterling-Winthrop nonpeptide bradykinin antagonist overlapped with cyclic hexapeptide bradykinin antagonist peptides

  摘要：

  A proposed overlap between cyclic hexapeptide Bradykinin antagonists and nonpeptide Bradykinin antagonists is discussed. Structural variations on both the peptides and nonpeptides support the proposed overlap based on an increase or decrease in the biological activities of the antagonists. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00328-4
• 作为产物：
  描述：

  (S)-4-[(S)-2-Acetylamino-3-(4-phosphonooxy-phenyl)-propionylamino]-4-((R)-1-carbamoyl-3-cyclohexyl-propylcarbamoyl)-butyric acid 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 {4-[[(R)-2-(N',N''-Dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionyl]-(3-oxo-propyl)-amino]-benzyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Nonpeptide bradykinin antagonist analogs based on a model of a Sterling-Winthrop nonpeptide bradykinin antagonist overlapped with cyclic hexapeptide bradykinin antagonist peptides

  摘要：

  A proposed overlap between cyclic hexapeptide Bradykinin antagonists and nonpeptide Bradykinin antagonists is discussed. Structural variations on both the peptides and nonpeptides support the proposed overlap based on an increase or decrease in the biological activities of the antagonists. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00328-4